Overview

Chemoradiotherapy in Unresectable Esophageal Cancer

Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This phase I/II clinical study is designed to evaluate the 1 year local tumor control rate of chemoradiotherapy using albumin-bound paclitaxel and cisplatin in unresectable esophageal squamous cell carcinomas based on Nutritional Risk Screening NRS2002.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Treatments:
Albumin-Bound Paclitaxel
Cisplatin
Paclitaxel